On March 11, 2021 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, reported the company will make six presentations at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021 being held April 10-15, 2021 in a virtual format (Press release, Revolution Medicines, MAR 11, 2021, View Source [SID1234576514]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the planned presentations are as follows:

Oral Presentation:

Title: Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers
Abstract Number:
LB001
Session: Late-Breaking Minisymposium 1
Date/Time: April 10, 2021 at 2:05 p.m. Eastern
Poster Presentations:

Title: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers
Abstract Number: 1260
Session: Novel Antitumor Agents
Date/Time: April 10, 2021 at 8:30 a.m. Eastern

Title: A next generation tri-complex KRASG12C(ON) inhibitor directly targets the active, GTP-bound state of mutant RAS and may overcome resistance to KRASG12C(OFF) inhibition
Abstract Number: 1261
Session: Novel Antitumor Agents
Date/Time: April 10, 2021 at 8:30 a.m. Eastern

Title: Discovery of a potent, selective, and orally bioavailable SOS1 inhibitor, RMC-023, an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction
Abstract Number:
1273
Session: Novel Antitumor Agents
Date/Time: April 10, 2021 at 8:30 a.m. Eastern

Title: Modulation of innate and adaptive immunity in blood and tumor of patients receiving the SHP2 inhibitor RMC-4630
Abstract Number: LB050
Session: Immune Response to Therapies
Date: April 10, 2021 at 8:30 a.m. Eastern

Title: Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical study
Abstract Number: LB054
Session: Liquid Biopsies: Circulating DNA
Date: April 10, 2021 at 8:30 a.m. Eastern
Additional information on the AACR (Free AACR Whitepaper) Annual Meeting 2021 is available through the AACR (Free AACR Whitepaper) website at: View Source